|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arnedos M, Vicier C, Loi S, Lefebvre C,
Michiels S, Bonnefoi H and Andre F: Precision medicine for
metastatic breast cancer-limitations and solutions. Nat Rev Clin
Oncol. 12:693–704. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cancer Genome Atlas Network: Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lumachi F, Santeufemia DA and Basso SM:
Current medical treatment of estrogen receptor-positive breast
cancer. World J Biol Chem. 6:231–239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ross JS, Slodkowska EA, Symmans WF,
Pusztai L, Ravdin PM and Hortobagyi GN: The HER-2 receptor and
breast cancer: Ten years of targeted anti-HER-2 therapy and
personalized medicine. Oncologist. 14:320–368. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Steward L, Conant L, Gao F and
Margenthaler J: Predictive factors and patterns of recurrence in
patients with triple negative breast cancer. Ann Surg Oncol.
21:2165–2171. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hassett MJ, O'Malley AJ, Pakes JR,
Newhouse JP and Earle CC: Frequency and cost of
chemotherapy-related serious adverse effects in a population sample
of women with breast cancer. J Natl Cancer Inst. 98:1108–1117.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liedtke C, Mazouni C, Hess KR, André F,
Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B,
Green M, et al: Response to neoadjuvant therapy and long-term
survival in patients with triple-negative breast cancer. J Clin
Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shang Y, Myers M and Brown M: Formation of
the androgen receptor transcription complex. Mol Cell. 9:601–610.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McNamara KM, Moore NL, Hickey TE, Sasano H
and Tilley WD: Complexities of androgen receptor signalling in
breast cancer. Endocr Relat Cancer. 21:T161–T181. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yeh S, Hu Y, Wang P, Xie C, Xu Q, Tsai M,
Dong Z, Wang R, Lee T and Chang C: Abnormal mammary gland
development and growth retardation in female mice and MCF7 breast
cancer cells lacking androgen receptor. J Exp Med. 198:1899–1908.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Niemeier LA, Dabbs DJ, Beriwal S, Striebel
JM and Bhargava R: Androgen receptor in breast cancer: Expression
in estrogen receptor-positive tumors and in estrogen
receptor-negative tumors with apocrine differentiation. Mod Pathol.
23:205–212. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Park S, Koo JS, Kim MS, Park HS, Lee JS,
Lee JS, Kim SI, Park BW and Lee KS: Androgen receptor expression is
significantly associated with better outcomes in estrogen
receptor-positive breast cancers. Ann Oncol. 22:1755–1762. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Goldenberg IS: Testosterone propionate
therapy in breast cancer. JAMA. 188:1069–1072. 1964. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Garay JP and Park BH: Androgen receptor as
a targeted therapy for breast cancer. Am J Cancer Res. 2:434–445.
2012.PubMed/NCBI
|
|
18
|
Chia K, O'Brien M, Brown M and Lim E:
Targeting the androgen receptor in breast cancer. Curr Oncol Rep.
17:42015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fujii R, Hanamura T, Suzuki T, Gohno T,
Shibahara Y, Niwa T, Yamaguchi Y, Ohnuki K, Kakugawa Y, Hirakawa H,
et al: Increased androgen receptor activity and cell proliferation
in aromatase inhibitor-resistant breast carcinoma. J Steroid
Biochem Mol Biol. 144:513–522. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Maugeri-Saccà M, Barba M, Vici P, Pizzuti
L, Sergi D, De Maria R and Di Lauro L: Aromatase inhibitors for
metastatic male breast cancer: Molecular, endocrine, and clinical
considerations. Breast Cancer Res Treat. 147:227–235. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qi JP, Yang YL, Zhu H, Wang J, Jia Y, Liu
N, Song YJ, Zan LK, Zhang X, Zhou M, et al: Expression of the
androgen receptor and its correlation with molecular subtypes in
980 chinese breast cancer patients. Breast Cancer (Auckl). 6:1–8.
2012.PubMed/NCBI
|
|
22
|
McNamara KM, Yoda T, Takagi K, Miki Y,
Suzuki T and Sasano H: Androgen receptor in triple negative breast
cancer. J Steroid Biochem Mol Biol. 133:66–76. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu H, Eirew P, Mullaly SC and Aparicio S:
The omics of triple-negative breast cancers. Clin Chem. 60:122–133.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lehmann BD, Bauer JA, Schafer JM,
Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H,
Arteaga CL, et al: PIK3CA mutations in androgen receptor-positive
triple negative breast cancer confer sensitivity to the combination
of PI3K and androgen receptor inhibitors. Breast Cancer Res.
16:4062014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American Society of
Clinical Oncology/College of American Pathologists clinical
practice guideline update. Arch Pathol Lab Med. 138:241–256. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shi SR, Guo J, Cote RJ, Young L, Hawes D,
Shi Y, Thu S and Taylor CR: Sensitivity and detection efficiency of
a novel two-step detection system (PowerVision) for
immunohistochemistry. Appl Immunohistochem. 7:201–208. 1999.
View Article : Google Scholar
|
|
27
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chia KM, Liu J, Francis GD and Naderi A: A
feedback loop between androgen receptor and ERK signaling in
estrogen receptor-negative breast cancer. Neoplasia. 13:154–166.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Micello D, Marando A, Sahnane N, Riva C,
Capella C and Sessa F: Androgen receptor is frequently expressed in
HER2-positive, ER/PR-negative breast cancers. Virchows Arch.
457:467–476. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Robinson JL, Macarthur S, Ross-Innes CS,
Tilley WD, Neal DE, Mills IG and Carroll JS: Androgen receptor
driven transcription in molecular apocrine breast cancer is
mediated by FoxA1. EMBO J. 30:3019–3027. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rakha EA, El-Sayed ME, Green AR, Lee AH,
Robertson JF and Ellis IO: Prognostic markers in triple-negative
breast cancer. Cancer. 109:25–32. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
McNamara KM, Yoda T, Miki Y, Chanplakorn
N, Wongwaisayawan S, Incharoen P, Kongdan Y, Wang L, Takagi K, Mayu
T, et al: Androgenic pathway in triple negative invasive ductal
tumors: Its correlation with tumor cell proliferation. Cancer Sci.
104:639–646. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Thike AA, Chong Yong-Zheng L, Cheok PY, Li
HH, Yip Wai-Cheong G, Bay Huat B, Tse GM, Iqbal J and Tan PH: Loss
of androgen receptor expression predicts early recurrence in
triple-negative and basal-like breast cancer. Mod Pathol.
27:352–360. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Choi JE, Kang SH, Lee SJ and Bae YK:
Androgen receptor expression predicts decreased survival in early
stage triple-negative breast cancer. Ann Surg Oncol. 22:82–89.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hammond ME, Hayes DF, Dowsett M, Allred
DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS,
Hayes M, et al: American Society of Clinical Oncology/College of
American Pathologists guideline recommendations for
immunohistochemical testing of estrogen and progesterone receptors
in breast cancer (unabridged version). Arch Pathol Lab Med.
134:e48–e72. 2010.PubMed/NCBI
|
|
36
|
Zhang L, Fang C, Xu X, Li A, Cai Q and
Long X: Androgen receptor, EGFR, and BRCA1 as biomarkers in
triple-negative breast cancer: A meta-analysis. Biomed Res Int.
2015:3574852015.PubMed/NCBI
|
|
37
|
Mrklić I, Pogorelić Z, Ćapkun V and Tomić
S: Expression of androgen receptors in triple negative breast
carcinomas. Acta Histochem. 115:344–348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ricciardi GR, Adamo B, Ieni A, Licata L,
Cardia R, Ferraro G, Franchina T, Tuccari G and Adamo V: Androgen
receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel
prognostic markers in triple-negative breast cancer (TNBC)
patients. PloS One. 10:e01283682015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Honma N, Horii R, Iwase T, Saji S, Saji S,
Younes M, Takubo K, Matsuura M, Ito Y, Akiyama F and Sakamoto G:
Clinical importance of estrogen receptor-beta evaluation in breast
cancer patients treated with adjuvant tamoxifen therapy. J Clin
Oncol. 26:3727–3734. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Anestis A, Karamouzis MV, Dalagiorgou G
and Papavassiliou AG: Is androgen receptor targeting an emerging
treatment strategy for triple negative breast cancer? Cancer Treat
Rev. 41:547–553. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Loibl S, Müller BM, von Minckwitz G,
Schwabe M, Roller M, Darb-Esfahani S, Ataseven B, du Bois A,
Fissler-Eckhoff A, Gerber B, et al: Androgen receptor expression in
primary breast cancer and its predictive and prognostic value in
patients treated with neoadjuvant chemotherapy. Breast Cancer Res
Treat. 130:477–487. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lehmann BD and Pietenpol JA:
Identification and use of biomarkers in treatment strategies for
triple-negative breast cancer subtypes. J Pathol. 232:142–150.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Luo X, Shi YX, Li ZM and Jiang WQ:
Expression and clinical significance of androgen receptor in triple
negative breast cancer. Chin J Cancer. 29:585–590. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gasparini P, Fassan M, Cascione L, Guler
G, Balci S, Irkkan C, Paisie C, Lovat F, Morrison C, Zhang J, et
al: Androgen receptor status is a prognostic marker in non-basal
triple negative breast cancers and determines novel therapeutic
options. PLoS One. 9:e885252014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Vera-Badillo FE, Templeton AJ, de Gouveia
P, Diaz-Padilla I, Bedard PL, Al-Mubarak M, Seruga B, Tannock IF,
Ocana A and Amir E: Androgen receptor expression and outcomes in
early breast cancer: A systematic review and meta-analysis. J Natl
Cancer Inst. 106:djt3192014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hu R, Dawood S, Holmes MD, Collins LC,
Schnitt SJ, Cole K, Marotti JD, Hankinson SE, Colditz GA and Tamimi
RM: Androgen receptor expression and breast cancer survival in
postmenopausal women. Clin Cancer Res. 17:1867–1874. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sutton LM, Cao D, Sarode V, Molberg KH,
Torgbe K, Haley B and Peng Y: Decreased androgen receptor
expression is associated with distant metastases in patients with
androgen receptor-expressing triple-negative breast carcinoma. Am J
Clin Pathol. 138:511–516. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
McGhan LJ, McCullough AE, Protheroe CA,
Dueck AC, Lee JJ, Nunez-Nateras R, Castle EP, Gray RJ, Wasif N,
Goetz MP, et al: Androgen receptor-positive triple negative breast
cancer: A unique breast cancer subtype. Ann Surg Oncol. 21:361–367.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Doane AS, Danso M, Lal P, Donaton M, Zhang
L, Hudis C and Gerald WL: An estrogen receptor-negative breast
cancer subset characterized by a hormonally regulated
transcriptional program and response to androgen. Oncogene.
25:3994–4008. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Tsutsumi Y: Apocrine carcinoma as
triple-negative breast cancer: Novel definition of apocrine-type
carcinoma as estrogen/progesterone receptor-negative and androgen
receptor-positive invasive ductal carcinoma. Jpn J Clin Oncol.
42:375–386. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Komura K, Sweeney CJ, Inamoto T, Ibuki N,
Azuma H and Kantoff PW: Current treatment strategies for advanced
prostate cancer. Int J Urol. 2017.
|
|
52
|
Loblaw DA, Virgo KS, Nam R, Somerfield MR,
Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott
J, et al: Initial hormonal management of androgen-sensitive
metastatic, recurrent, or progressive prostate cancer: 2006 update
of an American Society of Clinical Oncology practice guideline. J
Clin Oncol. 25:1596–1605. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Cuenca-López MD, Montero JC, Morales JC,
Prat A, Pandiella A and Ocana A: Phospho-kinase profile of triple
negative breast cancer and androgen receptor signaling. BMC Cancer.
14:3022014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Gucalp A, Tolaney S, Isakoff SJ, Ingle JN,
Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, et al:
Phase II Trial of bicalutamide in patients with androgen
receptor-positive, estrogen receptor-negative metastatic breast
cancer. Clin Cancer Res. 19:5505–5512. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Traina TA, Miller K, Yardley DA, Eakle J,
Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E,
Kelly C, et al: Enzalutamide for the treatment of androgen
receptor-expressing triple-negative breast cancer. J Clin Oncol.
JCO20167134952018.
|
|
56
|
Attard G, Reid AH, A'Hern R, Parker C,
Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, et
al: Selective inhibition of CYP17 with abiraterone acetate is
highly active in the treatment of castration-resistant prostate
cancer. J Clin Oncol. 27:3742–3748. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
O'Shaughnessy J, Campone M, Brain E, Neven
P, Hayes D, Bondarenko I, Griffin TW, Martin J, De Porre P, Kheoh
T, et al: Abiraterone acetate, exemestane or the combination in
postmenopausal patients with estrogen receptor-positive metastatic
breast cancer. Ann Oncol. 27:106–113. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Narayanan R, Coss CC and Dalton JT:
Development of selective androgen receptor modulators (SARMs). Mol
Cell Endocrinol: pii. S0303-7207(17)30340-4. 2017.
|
|
59
|
Narayanan R, Ahn S, Cheney MD, Yepuru M,
Miller DD, Steiner MS and Dalton JT: Selective Androgen receptor
modulators (SARMs) negatively regulate triple-negative breast
cancer growth and epithelial: Mesenchymal stem cell signaling. PLoS
One. 9:e1032022014. View Article : Google Scholar : PubMed/NCBI
|
